Ultragenyx Pharmaceutical's CEO will present at the J.P. Morgan Healthcare Conference on January 12, 2026.
Quiver AI Summary
Ultragenyx Pharmaceutical Inc. announced that its CEO Emil D. Kakkis will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 10:30 AM PT. The presentation will be available as a live and archived webcast on the company’s website. Ultragenyx, a biopharmaceutical company, focuses on developing therapies for rare genetic diseases and has a portfolio of approved treatments aimed at addressing high unmet medical needs. The company emphasizes efficient drug development to provide safe and effective therapies swiftly. More information can be found on their website.
Potential Positives
- Ultragenyx will be presenting at the prestigious 44th Annual J.P. Morgan Healthcare Conference, which highlights the company's visibility and reputation within the biopharmaceutical industry.
- The presentation by CEO Emil D. Kakkis emphasizes strong leadership and communication from the company's top executive, potentially boosting investor confidence.
- The company has a diverse portfolio of approved therapies and product candidates, showcasing its commitment to addressing high unmet medical needs in rare and ultra-rare genetic diseases.
Potential Negatives
- None
FAQ
When will Ultragenyx present at the J.P. Morgan Healthcare Conference?
Ultragenyx will present on January 12, 2026, at 10:30 AM PT.
How can I access the live webcast of the presentation?
The live webcast can be accessed from Ultragenyx’s website at https://ir.ultragenyx.com/events-presentations.
Will the presentation be available for replay?
Yes, the replay of the presentation will be available for 30 days after the event.
What is the focus of Ultragenyx Pharmaceutical Inc.?
Ultragenyx focuses on developing therapies for serious rare and ultra-rare genetic diseases.
What is Ultragenyx’s drug development strategy?
Ultragenyx aims for time- and cost-efficient drug development to deliver safe and effective therapies urgently.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RARE Insider Trading Activity
$RARE insiders have traded $RARE stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $RARE stock by insiders over the last 6 months:
- HOWARD HORN (Chief Financial Officer) has made 0 purchases and 2 sales selling 11,023 shares for an estimated $362,339.
- KARAH HERDMAN PARSCHAUER (EVP and Chief Legal Officer) sold 2,450 shares for an estimated $76,366
- THEODORE ALAN HUIZENGA (SVP, Chief Accounting Officer) has made 0 purchases and 3 sales selling 233 shares for an estimated $7,425.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RARE Congressional Stock Trading
Members of Congress have traded $RARE stock 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $RARE stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 2 purchases worth up to $30,000 on 08/08, 07/15 and 0 sales.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$RARE Hedge Fund Activity
We have seen 177 institutional investors add shares of $RARE stock to their portfolio, and 142 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 4,678,708 shares (+179.6%) to their portfolio in Q3 2025, for an estimated $140,735,536
- CLEARBRIDGE INVESTMENTS, LLC removed 1,984,825 shares (-92.7%) from their portfolio in Q3 2025, for an estimated $59,703,536
- JACOBS LEVY EQUITY MANAGEMENT, INC added 1,864,164 shares (+614.1%) to their portfolio in Q3 2025, for an estimated $56,074,053
- ALKEON CAPITAL MANAGEMENT LLC removed 1,685,729 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $50,706,728
- FEDERATED HERMES, INC. removed 1,553,441 shares (-75.8%) from their portfolio in Q3 2025, for an estimated $46,727,505
- DEEP TRACK CAPITAL, LP removed 1,350,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $40,608,000
- ALLIANCEBERNSTEIN L.P. removed 1,228,495 shares (-97.9%) from their portfolio in Q3 2025, for an estimated $36,953,129
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RARE Analyst Ratings
Wall Street analysts have issued reports on $RARE in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Leerink Partners issued a "Outperform" rating on 12/30/2025
- Baird issued a "Outperform" rating on 12/30/2025
- Barclays issued a "Overweight" rating on 11/24/2025
- TD Cowen issued a "Buy" rating on 11/05/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/09/2025
- Cantor Fitzgerald issued a "Overweight" rating on 09/05/2025
- Canaccord Genuity issued a "Buy" rating on 08/08/2025
To track analyst ratings and price targets for $RARE, check out Quiver Quantitative's $RARE forecast page.
$RARE Price Targets
Multiple analysts have issued price targets for $RARE recently. We have seen 14 analysts offer price targets for $RARE in the last 6 months, with a median target of $59.0.
Here are some recent targets:
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $60.0 on 01/05/2026
- Debjit Chattopadhyay from Guggenheim set a target price of $52.0 on 01/05/2026
- Tazeen Ahmad from B of A Securities set a target price of $58.0 on 01/02/2026
- Joel Beatty from Baird set a target price of $47.0 on 12/30/2025
- Benjamin Burnett from Wells Fargo set a target price of $45.0 on 12/30/2025
- Maury Raycroft from Jefferies set a target price of $63.0 on 12/30/2025
- Joseph Schwartz from Leerink Partners set a target price of $70.0 on 12/30/2025
Full Release
NOVATO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will present at the 44 th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 10:30 AM PT.
The live and archived webcast of the presentation will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations . The replay of the webcast will be available for 30 days.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com .
Contact – Ultragenyx Pharmaceutical, Inc.
Investors
Joshua Higa
[email protected]
